Solicitation No.: NIHDA201800379

Project Title: Angiogenesis Assay System

Classification Code: 65 - Medical, dental & Veterinary Equipment & Supplies

NAICS Code: 325411 - Medicinal and Botanical Manufacturing, 1,000 Employees

This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice.

Please note that to qualify as an eligible small business for purposes of a small business set-aside, at least 50% of the cost of contract performance incurred for personnel must be expended for employees of the small business awardee (see FAR 52.219-14 Limitations on Subcontracting).

Purpose and Objectives

The National Institutes of Health (NIH) is the nation's leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people's health and save lives. The National Center for Advancing Translational Sciences (NCATS) is a translational science center that prides itself on its tremendously productive pipeline and is innovative in several ways. NCATS brings together a diverse range of scientists, including medicinal chemists, biologists, toxicologists, and engineers, in to ultimately translate basic science into real products and services that help improve people's lives.

NCATS requires Angiogenesis Assay System and these assay kits will be used to screen compounds from Tox21 collaboration. Tox21 collaboration between NCATS, NTP, EPA and FDA started off with an aim to screen tens and thousands of known drugs and compounds in vitro by reducing the cost and time-consuming processes involved in traditional toxicity testing methods. Since its inception nearly a decade ago, several screenings against Tox21 compound collection were performed at NCATS by running cell based assays that are focusing mainly on different targets and toxicity pathways which include nuclear receptor signaling, stress response, developmental toxicology, GPCR/cAMP signaling, and Epigentics etc. All these assays used either luciferase or fluorescence reporter gene technology for readouts. In order to quantify the induction/inhibition of these reporter gene activities, different detection assay systems have been used. In the past we tested angiogenesis assay to screen compounds from NPC library, and successfully identified the angiogenesis inhibitors.

NCATS is seeking a Brand-Name or Equal to Angio-Ready Angiogenesis Assay 10 plates per pack, Item No. ACS-2001-10.

Project Requirements

In their Capability Statement, respondents shall address the following requirements:

• The assay system is extremely user-friendly, as it contains all of the biological components needed for angiogenesis to occur and are reminiscent of the in vivo situation.
• Though it is configured for a 96-well plate, the assay was validated in a 1,536-well plate by screening a set of library compounds and the assay performed well in identifying angiogenesis inhibitors.
• It is an assay-ready, pre-mixed co-culture of human telomerase-immortalized (hTERT) human aortic endothelial cells that express green fluorescent protein and hTERT mesenchymal stem cells produce a vascular network reminiscent of in vivo angiogenesis.
• The co-culture high-content angiogenesis assay is useful for the profiling of angiogenesis inhibitors in drug screening.

Anticipated Delivery

The Government requires a one-time delivery within 60 days of award of a contract.

Required Information

All capability statements must provide the following: (1) DUNS number; (2) organization name; (3) organization address; (4) point of contact; (5) point of contact title, address, telephone, and email address; and (6) size and type of business (e.g., 8(a), HUBZone, etc.) pursuant the applicable NAICS code.

Submission Instructions and Due Date

Written capability statements must be SUBMITTED NO LATER THAN TUESDAY, JULY 31, 2018 to the below Contracting Office Address, Attn: Donna Morris. Electronic capability statements will be accepted by the primary point of contact.

Disclaimer and Important Notes

This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation.

Confidentiality

No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).

Contracting Office Address

NCATS Section
NIDA Office of Acquisition
6001 Executive Boulevard
Suite 3154, MSC 9531
Bethesda, Maryland 20892-9531*

*Use Rockville, MD 20852 for Fed-Ex/USPS/Courier/Hand-Delivery

Points of Contact

Primary Point of Contact:
Donna Morris
Contracting Officer
[email protected]
Phone: (301) 496-2076